Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter Zepbound beats CagriSema in head to head trial : r Zepbound Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question When do we choose semaglotide and when does terzipatide? EASO has just announced that it will update its algorithm with evidence until November 2025 Warning: It depends on the clinical goal.